75 citations
,
September 2015 in “Acta biomaterialia” This study found that alkylation of kerateine cysteine residues created a cell-compatible method for controlling hydrogel erosion rates and therapeutic agent release in keratin-based systems.
54 citations
,
January 2023 in “Signal Transduction and Targeted Therapy” This review examines integrins as pharmacological targets, discussing current integrin-based therapies and emphasizing the need to understand integrin mechanisms for successful drug development, without reporting new clinical results.
15 citations
,
June 2021 in “Journal of Genetic Engineering and Biotechnology” This review explores biomaterials in non-viral gene delivery systems and highlights the need for more research to better understand how various parameters affect gene delivery processes, without reporting new experimental results.
11 citations
,
December 2020 in “Advanced structured materials” This book chapter reviews the role of natural products in cosmetics and their widespread use in skincare and haircare but reports no new results.
10 citations
,
September 2022 in “Advanced Healthcare Materials” This review discusses recent advancements and ongoing challenges in engineering human skin with appendages using scaffold-free and scaffold-based bioengineering approaches, but it reports no new clinical results.
9 citations
,
November 2024 in “Biotechnology for Sustainable Materials” This paper critically reviews recent advances in the use of keratin-based biomaterials, highlighting their potential applications in wound healing, drug delivery, and tissue regeneration due to their biocompatibility, biodegradability, and ability to support cell growth.
7 citations
,
January 2017 in “Clinical and medical investigations” This paper reviews the historical use and contemporary relevance of plant-derived cosmetics, focusing on Suriname's herbal cosmetics industry and the potential to establish a beauty products industry there, without presenting new findings.
6 citations
,
December 2022 in “Colloids and Surfaces B: Biointerfaces” This study reported that a novel bilayer wound dressing made from PLCL nanofibers and keratin hydrogel, loaded with FGF-2, promoted skin healing and showed potential for use in skin tissue engineering.
3 citations
,
June 2022 in “Cells” This study reports improved methods for harvesting and processing keratinocytes from plucked human hair, enhancing their utility in generating donor-specific induced pluripotent stem cells more efficiently and reliably.
2 citations
,
September 2024 in “Lasers in Surgery and Medicine” This study concluded that noninvasive imaging techniques offer potential benefits in managing scalp conditions by potentially reducing the need for biopsies and minimizing patient morbidity, each technique having unique advantages and limitations for specific conditions.
June 2025 in “Advances in Clinical and Experimental Medicine” This study highlights keratin biomaterials as a promising biocompatible option for wound healing and tissue regeneration but notes that further clinical studies are necessary to confirm their effectiveness.
12 citations
,
March 2004 in “International Journal of Dermatology” A woman with X-linked chronic granulomatous disease developed lupus-like skin lesions, improved with treatment, suggesting a unique skin condition in carriers.
December 2023 in “Journal of General Procedural Dermatology and Venereology Indonesia” The abstract highlights that lichen planus can manifest as cicatricial alopecia or lichen planopilaris, while discoid lupus erythematosus, a common form of lupus erythematosus, typically causes scarring alopecia. Results are not reported here.
5 citations
,
March 2019 in “Scandinavian journal of rheumatology” This article discusses the potential misdiagnosis issues in cutaneous manifestations of lupus erythematosus and reports no new research findings.
14 citations
,
January 2001 in “Current Treatment Options in Oncology” Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.
April 2025 in “European Journal of Pharmaceutics and Biopharmaceutics” This study developed and tested Bicalutamide-loaded lipid vesicles in dissolving microarray patches for topical application, finding that they effectively deliver Bicalutamide through murine skin while maintaining a favorable safety profile, suggesting potential to improve treatments for androgenetic alopecia.
13 citations
,
December 2017 in “Journal of Cosmetic and Laser Therapy” This study evaluated the use of low-level laser therapy for treating androgenic alopecia in adults, finding it a promising and safe at-home option for stimulating hair growth compared to sham devices, though further research is needed to confirm its clinical effectiveness.
107 citations
,
March 2014 in “BoneKEy Reports” This abstract reviews hereditary vitamin D-resistant rickets, a rare genetic condition causing severe early childhood rickets, and reports no new results; effective treatment typically requires high doses of calcium to address hypocalcemia and secondary hyperparathyroidism.
6 citations
,
November 2018 in “Photodiagnosis and Photodynamic Therapy” This study found that using a wearable low-level light therapy device for photodynamic therapy significantly reduced actinic keratosis lesions and improved quality of life in patients with AK of the scalp.
1 citations
,
March 2015 in “Journal of the European Academy of Dermatology and Venereology” This letter to the editor shares a case study of lentiginous melanoma that appears clinically malignant but histopathologically benign, involving the BRAFV600R mutation.
January 2024 in “Wiadomości Lekarskie” This pilot clinical study introduces DEC cells as a novel therapy for Duchenne muscular dystrophy, confirming safety and efficacy in seven patients up to 24 months post-treatment.
1057 citations
,
November 2011 in “Annals of Biomedical Engineering” This review discusses the applications of low level laser therapy (LLLT) in wound healing, pain reduction, and treating various conditions, but reports no new clinical results; the authors highlight the need for randomized controlled trials for serious diseases.
June 2026 in “Lasers in Medical Science” This randomized trial found that diode laser achieved more favorable long-term hair removal outcomes but induced more discomfort and transient adverse effects compared to intense pulsed light in women with Fitzpatrick skin types I-IV.
90 citations
,
January 2009 in “Journal of cosmetic and laser therapy” In this study, low-level laser therapy showed no statistically significant improvements in hair growth measures, despite some patients experiencing increases in terminal hairs and shaft diameter.
October 2025 in “Dermatology Practical & Conceptual” In this study, UVFD and sUVRD techniques revealed distinctive characteristics of GD lesions, suggesting that GD might be more common in younger individuals and females than previously thought, possibly due to underdiagnosis. Incorporating dermatoscopy in exams may help improve GD detection and management.
This study observed that low-level laser therapy (LLLT) increased cell viability in SARS-CoV-2-uninfected HEK293/ACE2 cells but did not improve viability in infected cells, suggesting mixed effects.
This study found that low-level laser therapy may enhance wound healing and reduce pain, swelling, and inflammation by increasing mitochondrial activity and oxidative stress, leading to greater protein synthesis and cell proliferation.
April 2019 in “Journal of Investigative Dermatology” This review examines clinical trials on low-level laser therapy for pattern hair loss but reports no definitive conclusions, highlighting the need for more controlled studies to resolve uncertainties.
October 2013 in “CRC Press eBooks” This review outlines current and potential cosmetic and dermatological applications of low-level light therapy, like photorejuvenation and hair regrowth, and reports no new clinical findings.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.